What Are the Most Monitored Prescription Opioids

The most monitored prescription opioids are the ones that have produced the highest rates of diversion, dependence, and overdose death, and whose prescribing patterns most reliably distinguish therapeutic use from commercial distribution.

Every Schedule II and III controlled substance is subject to DEA monitoring through the Automation of Reports and Consolidated Orders System and through state prescription drug monitoring programs. The monitoring intensity varies by substance based on the substance’s abuse potential, its historical association with diversion, and the prescribing patterns that have been identified as diversion indicators. The substances described below receive the highest level of regulatory attention in the current enforcement environment.

Oxycodone

Oxycodone, marketed in immediate-release form and as the extended-release formulation OxyContin, is the prescription opioid most closely associated with the pill mill era and with the escalating prescribing that produced the epidemic’s first wave. Its high potency, its availability in high-dose formulations, and its historical association with recreational misuse and diversion have made it the pharmaceutical opioid whose prescribing receives the most intensive DEA scrutiny.

Prescribers whose oxycodone prescribing volume, dose levels, or patient population characteristics deviate from specialty norms are among the first-tier targets of DEA PDMP analysis. Oxycodone prescriptions to patients without documented chronic pain diagnoses, at doses exceeding guideline recommendations without documented clinical justification, or in combinations with benzodiazepines are the specific patterns that most reliably generate investigative referrals.

Hydrocodone

Hydrocodone, rescheduled from Schedule III to Schedule II by the DEA in 2014 in recognition of its high abuse potential, is the most commonly prescribed opioid in the United States. Its prevalence in prescribing data means that it appears in virtually every opioid fraud investigation as a component of the prescribing pattern under scrutiny, even where it is not the primary drug of concern.

The rescheduling of hydrocodone combination products in 2014 imposed Schedule II prescription requirements, including the prohibition on telephone prescriptions and refills, on a medication that had previously been prescribed with the relative flexibility of a Schedule III substance. Prescribers who continued to issue hydrocodone prescriptions after 2014 in a manner inconsistent with Schedule II requirements created compliance violations that are distinct from the medical necessity question but that contribute to the prescribing pattern the DEA assesses.

Fentanyl

Pharmaceutical fentanyl, prescribed in transdermal patches, buccal films, lozenges, and injectable forms, is the most potent prescription opioid in routine clinical use. Its prescribing is monitored with particular attention because of the severe consequences of its misuse and because the illicit fentanyl supply creates a specific diversion risk: patients who obtain pharmaceutical fentanyl prescriptions and sell them into the illicit market are supplying a product that is indistinguishable from illicitly manufactured fentanyl in the street drug supply.

The authorized uses of pharmaceutical fentanyl are specific and limited: primarily the management of breakthrough pain in cancer patients already receiving opioid maintenance therapy. Prescriptions of pharmaceutical fentanyl to patients who do not have cancer, who are not on established opioid therapy, or who are receiving fentanyl as a primary opioid analgesic rather than as breakthrough therapy are prescriptions outside the indications that most clinical guidelines recognize, and they generate DEA scrutiny accordingly.

Benzodiazepines and the Co-Prescribing Flag

While benzodiazepines are Schedule IV rather than Schedule II, their co-prescription with opioids is one of the most significant red flags in DEA prescribing analysis. The combination of opioids and benzodiazepines substantially increases the risk of fatal respiratory depression, and its prevalence in pill mill operations, where the combination was specifically sought by patients using the medications for their euphoric effects, has made the combination a standard investigative trigger.

PDMP analysis routinely identifies prescribers who co-prescribe opioids and benzodiazepines at rates exceeding specialty norms and who prescribe both medications to the same patients. Those patterns generate investigative attention independent of the individual prescribing volumes for either drug. The practitioner who co-prescribes these drugs for clinical reasons should document those reasons with particular specificity.

DEFENSE TEAM SPOTLIGHT

Todd Spodek

Lead Attorney & Founder

Featured on Netflix's "Inventing Anna," Todd Spodek brings decades of high-stakes criminal defense experience. His aggressive approach has secured dismissals and acquittals in cases others deemed unwinnable.

NY Bar Admitted Multi-State Licensed Federal Courts

Meet the Full Team

Stimulants in the Context of Combined Monitoring

Schedule II stimulants, including amphetamine formulations and methylphenidate, are monitored through the same PDMP infrastructure as opioids. Their relevance to the opioid enforcement context arises primarily when a prescriber’s PDMP data shows patterns of prescribing both stimulants and opioids to the same patient population at rates inconsistent with the clinical diagnoses that would support those combinations.

Legal Scenario: What Would You Do?

Scenario

Federal agents execute a search warrant at your medical practice, seizing patient records and prescription logs.

Can they take patient records without patient consent?

Attorney's Answer

A valid federal search warrant overrides HIPAA privacy protections. However, the warrant must be properly scoped. An attorney can challenge overly broad warrants and move to suppress improperly seized evidence.

This is general information only. Contact us for advice specific to your situation.

The most monitored prescription opioids are the ones that produced the most deaths. The monitoring is a direct response to the mortality data and the prescribing patterns that generated it. A prescriber who understands which substances attract the most scrutiny and why is a prescriber who can calibrate their compliance documentation to address the specific patterns that investigations are most likely to flag.

ARCOS Data and Distributor-Level Monitoring

The DEA’s ARCOS system monitors controlled substance distribution at the wholesale level, tracking every purchase of scheduled substances by every DEA registrant. ARCOS data was the basis for the civil litigation against pharmaceutical distributors that produced multi-billion-dollar settlements and was disclosed through discovery in a manner that documented the extraordinary volumes of opioids shipped to specific pharmacies and geographic areas. The ARCOS data provides the distributor-level equivalent of the PDMP’s prescriber-level monitoring, and the two data sets together provide the government with a comprehensive picture of controlled substance flows from manufacturer to patient.